Regulators cleared the first daily tablet in a popular class of obesity medicines, giving the U.S. drugmaker a lead over a rival still waiting on a similar decision.
Fact checked by NewsPlainVerified by NewsPlain: confirmed by at least two named sources
Brief
China's National Medical Products Administration approved Eli Lilly's once-daily orforglipron pills for long-term weight management in adults with obesity, or with overweight…
More reporting and context continue here.
The complete story is available with Premium.
Read the facts, open questions and supporting sources.
Continue reading with NewsPlain Premium.
Keep reading with NewsPlain Premium
Get the full brief, the full story, what's confirmed, what's still unclear, why it matters, and every source.
5 confirmed facts, 2 open questions and 2 sources behind this story.